Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome.

BACKGROUND

Choroid plexus (ChP) enlargement is an emerging radiological biomarker in multiple sclerosis (MS).

OBJECTIVES

This study aims to assess ChP volume in a large cohort of patients with radiologically isolated syndrome (RIS) versus healthy controls (HC) and explore its relationship with other brain volumes, disease activity, and biological markers.

METHODS

RIS individuals were included retrospectively and compared with HC. ChPs were automatically segmented using an in-house automated algorithm and manually corrected.

RESULTS

A total of 124 patients fulfilled the 2023 RIS criteria, and 55 HCs were included. We confirmed that ChPs are enlarged in RIS versus HC (mean (±SD) normalized ChP volume: 17.24 (±4.95) and 11.61 (±3.58), respectively,

CONCLUSIONS

This study provides evidence that ChP volume is higher in RIS and is associated with measures reflecting periventricular pathology but does not correlate with biological, radiological, or clinical markers of disease activity.

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C.L.-C. received a Neuromod Institute grant for her PhD.VAGR reports fees for traveling from Novartis, Merck, Biogen, and Roche, speaker’s honoraria from Novartis, Sandoz, Merck, Biogen, Roche, consulting fees from Biogen, Merck, Novartis, Janssen, M3 Global Research, and Atheneum Partners, all outside of the submitted work.L. M. has no conflict of interest.E. T. received consulting and lecturing fees, travel grants, or unconditional research support from the following pharmaceutical companies: Actelion, Biogen, BMS, Janssen, Merck, Novartis, Roche, and Teva Pharma.P. L. has no financial conflicts related to this work.C. L. has received speaker or consulting fees from Biogen, Merck, Novartis, Sanofi, and Roche and a research grant (to the institution) from Biogen.H. Z. has no disclosure related to this work. HZ received consulting fees from ALEXION, HORIZON THERAPEUTICS, ROCHE, BIOGEN IDEC, SANOFI, JANSSEN, and research support from ROCHE and NOVARTIS.F. D.D. has no financial conflicts related to this work.E. L.P. has no financial conflicts related to this work.A. S. has no financial conflicts related to this work and has received research grants from The Turkish Multiple Sclerosis Society, The Scientific and Technological Research Council Of Turkiye, and Istanbul University-Cerrahpasa Research Support Funds. He has received consultancy fees from Roche Ltd, Merck-Serono, Biogen Idec/Gen Pharma of Turkiye, Sanofi-Genzyme, Novartis, and Alexion and received honoraria for lectures from Sanofi-Genzyme, Novartis, Roche Ltd., and Teva—registration coverage for attending scientific congresses or symposia from Sanofi-Genzyme and Alexion.M. C. has no conflict of interest.A. YP. has no financial conflicts related to this work.C. J.A. has no conflict of interest with this work.D. T.O. received personal compensation for consulting and advisory services from Biogen, Eisai, EMD Serono, Genentech, Genzyme/Sanofi, Moderna, RVL Pharmaceuticals, Inc., Zenas BioPharma, and research support from EMD Serono/Merck and Novartis. D.T.O. has issued national and international patents and pending patents related to other developed technologies. D.T.O. received royalties for intellectual property licensed by The Board of Regents of The University of Texas System and is also the Founder of Revert Health Inc.B. S. has received personal speaker fees from Janssen, Biogen, Novartis, Merck, and Sanofi, as well as research support (to the institution) from Merck, Roche, and Novartis.C. L-F. has no conflict of interest.